These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1385 related items for PubMed ID: 28821519

  • 1. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials.
    Lehtinen M, Lagheden C, Luostarinen T, Eriksson T, Apter D, Harjula K, Kuortti M, Natunen K, Palmroth J, Petäjä T, Pukkala E, Siitari-Mattila M, Struyf F, Nieminen P, Paavonen J, Dubin G, Dillner J.
    BMJ Open; 2017 Aug 18; 7(8):e015867. PubMed ID: 28821519
    [Abstract] [Full Text] [Related]

  • 2. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G, HPV PATRICIA Study Group.
    Lancet Oncol; 2012 Jan 18; 13(1):89-99. PubMed ID: 22075171
    [Abstract] [Full Text] [Related]

  • 3. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M, HPV PATRICIA Study Group.
    Lancet Oncol; 2012 Jan 18; 13(1):100-10. PubMed ID: 22075170
    [Abstract] [Full Text] [Related]

  • 4. Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ-population-based follow-up of two cluster-randomized trials.
    Lehtinen M, Gray P, Luostarinen T, Eriksson T, Apter D, Bly A, Harjula K, Heikkilä K, Hokkanen M, Kuortti M, Nieminen P, Nummela M, Paavonen J, Palmroth J, Petäjä T, Pimenoff VN, Pukkala E, Dillner J.
    Front Cell Infect Microbiol; 2024 Jan 18; 14():1437704. PubMed ID: 39315334
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial.
    Porras C, Tsang SH, Herrero R, Guillén D, Darragh TM, Stoler MH, Hildesheim A, Wagner S, Boland J, Lowy DR, Schiller JT, Schiffman M, Schussler J, Gail MH, Quint W, Ocampo R, Morales J, Rodríguez AC, Hu S, Sampson JN, Kreimer AR, Costa Rica Vaccine Trial Group.
    Lancet Oncol; 2020 Dec 18; 21(12):1643-1652. PubMed ID: 33271093
    [Abstract] [Full Text] [Related]

  • 6. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.
    Shing JZ, Hu S, Herrero R, Hildesheim A, Porras C, Sampson JN, Schussler J, Schiller JT, Lowy DR, Sierra MS, Carvajal L, Kreimer AR, Costa Rica HPV Vaccine Trial Group.
    Lancet Oncol; 2022 Jul 18; 23(7):940-949. PubMed ID: 35709811
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
    Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow SN, Kitchener HC, Teixeira JC, Jaisamrarn U, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Mindel A, de Sutter P, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group.
    Clin Vaccine Immunol; 2015 Apr 18; 22(4):361-73. PubMed ID: 25651922
    [Abstract] [Full Text] [Related]

  • 10. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
    Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmerón J, Del Rosario-Raymundo MR, Verheijen RH, Quek SC, da Silva DP, Kitchener H, Fong KL, Bouchard C, Money DM, Ilancheran A, Cruickshank ME, Levin MJ, Chatterjee A, Stapleton JT, Martens M, Quint W, David MP, Meric D, Hardt K, Descamps D, Geeraerts B, Struyf F, Dubin G, VIVIANE Study Group.
    Lancet; 2014 Dec 20; 384(9961):2213-27. PubMed ID: 25189358
    [Abstract] [Full Text] [Related]

  • 11. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing.
    Lehtinen M, Apter D, Dubin G, Kosunen E, Isaksson R, Korpivaara EL, Kyhä-Osterlund L, Lunnas T, Luostarinen T, Niemi L, Palmroth J, Petäjä T, Rekonen S, Salmivesi S, Siitari-Mattila M, Svartsjö S, Tuomivaara L, Vilkki M, Pukkala E, Paavonen J.
    Int J STD AIDS; 2006 Aug 20; 17(8):517-21. PubMed ID: 16925896
    [Abstract] [Full Text] [Related]

  • 12. Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up.
    Rana MM, Huhtala H, Apter D, Eriksson T, Luostarinen T, Natunen K, Paavonen J, Pukkala E, Lehtinen M.
    Int J Cancer; 2013 Jun 15; 132(12):2833-8. PubMed ID: 23180157
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
    Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group.
    Lancet; 2009 Jul 25; 374(9686):301-14. PubMed ID: 19586656
    [Abstract] [Full Text] [Related]

  • 14. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial.
    Garland SM, Paavonen J, Jaisamrarn U, Naud P, Salmerón J, Chow SN, Apter D, Castellsagué X, Teixeira JC, Skinner SR, Hedrick J, Limson G, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Germar MJ, Peters K, Del Rosario-Raymundo MR, Catteau G, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group.
    Int J Cancer; 2016 Dec 15; 139(12):2812-2826. PubMed ID: 27541373
    [Abstract] [Full Text] [Related]

  • 15. Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial.
    Lehtinen M, Lagheden C, Luostarinen T, Eriksson T, Apter D, Bly A, Gray P, Harjula K, Heikkilä K, Hokkanen M, Karttunen H, Kuortti M, Nieminen P, Nummela M, Paavonen J, Palmroth J, Petäjä T, Pukkala E, Soderlund-Strand A, Veivo U, Dillner J.
    BMJ Open; 2021 Dec 30; 11(12):e050669. PubMed ID: 35149535
    [Abstract] [Full Text] [Related]

  • 16. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
    Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, Salmerón J, McNeil S, Stapleton JT, Bouchard C, Martens MG, Money DM, Quek SC, Romanowski B, Vallejos CS, Ter Harmsel B, Prilepskaya V, Fong KL, Kitchener H, Minkina G, Lim YKT, Stoney T, Chakhtoura N, Cruickshank ME, Savicheva A, da Silva DP, Ferguson M, Molijn AC, Quint WGV, Hardt K, Descamps D, Suryakiran PV, Karkada N, Geeraerts B, Dubin G, Struyf F, VIVIANE Study Group.
    Lancet Infect Dis; 2016 Oct 30; 16(10):1154-1168. PubMed ID: 27373900
    [Abstract] [Full Text] [Related]

  • 17. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.
    Health Technol Assess; 2014 Apr 30; 18(23):1-196. PubMed ID: 24762804
    [Abstract] [Full Text] [Related]

  • 18. Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial.
    Zhao S, Hu S, Xu X, Zhang X, Pan Q, Chen F, Zhao F.
    BMC Infect Dis; 2020 Nov 16; 20(1):846. PubMed ID: 33198657
    [Abstract] [Full Text] [Related]

  • 19. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
    Egli-Gany D, Spaar Zographos A, Diebold J, Masserey Spicher V, Frey Tirri B, Heusser R, Dillner J, Petignat P, Sahli R, Low N, CIN3+plus study group.
    BMC Cancer; 2019 Jan 30; 19(1):111. PubMed ID: 30700274
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
    Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G, HPV PATRICIA study group.
    Lancet; 2007 Jun 30; 369(9580):2161-2170. PubMed ID: 17602732
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.